Haloperidol Decanoat Neuraxpharm (Haloperidol Decanoate)

Haloperidol Decanoate Neuraxpharm is indicated for several psychiatric conditions where a long‑acting injectable antipsychotic is preferred to improve adherence and provide stable drug exposure.

• Schizophrenia, including maintenance therapy after acute stabilization, to reduce relapse risk.
• Acute psychotic episodes when rapid symptom control is needed and oral administration is impractical.
• Long‑term relapse prevention in patients with a documented history of recurrent psychotic episodes.
• Tourette syndrome, as an adjunct for severe motor and vocal tics unresponsive to first‑line agents.
• Clinician‑guided off‑label use for other chronic psychotic disorders where depot therapy may be beneficial.

The safety profile of haloperidol decanoate reflects its pharmacologic activity as a dopamine antagonist, with both expected and less frequent adverse events that clinicians monitor during therapy.

Common

• Sedation or drowsiness, especially after injection.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.
• Weight gain or changes in appetite.
• Blurred vision or visual disturbances.
• Nausea or vomiting.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary movements of the face or limbs.
• Severe hypotension or cardiac arrhythmias.
• Hyperprolactinemia leading to menstrual disturbances or galactorrhea.
• Agranulocytosis or severe leukopenia (very uncommon).

When prescribing haloperidol decanoate, healthcare professionals should consider several precautionary measures to minimize risks and ensure appropriate patient selection.

• Assess cardiovascular status, especially for patients with a history of arrhythmias or hypotension.
• Evaluate for prior extrapyramidal reactions or tardive dyskinesia before initiating therapy.
• Use caution in patients with hepatic or renal impairment, adjusting monitoring as needed.
• Discuss potential pregnancy and lactation risks, as safety data are limited.
• Monitor prolactin levels regularly to detect hyperprolactinemia.
• Review concomitant medications that may prolong QT interval.
• Ensure patients understand the importance of adherence to scheduled injections.

Haloperidol decanoate may interact with other drugs that influence dopamine pathways, cardiac conduction, or metabolic clearance, requiring careful review of a patient’s medication list.

Avoid

• Other antipsychotics or dopamine antagonists, which can increase the risk of extrapyramidal symptoms and sedation.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise haloperidol plasma concentrations.

Use with caution

• CYP3A4 inducers such as carbamazepine or rifampin, which could reduce drug exposure.
• Medications that prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics).
• Central nervous system depressants, including benzodiazepines or opioids, which may enhance sedation.
• Anticholinergic agents, which can mask early signs of extrapyramidal side effects.